期刊文献+

替吉奥胶囊单药治疗晚期胃癌的临床观察 被引量:14

Clinical Observation of S1 Capsule for Advanced Gastric Cancer
暂未订购
导出
摘要 目的探讨替吉奥胶囊单药治疗晚期胃癌的疗效与不良反应。方法 2009年1月~2011年1月,22例晚期胃癌患者采用口服替吉奥胶囊60 mg/次,一日2次,连续2周停1周,3周重复,连用2周期。按RECIST1.1标准评价客观疗效和不良反应。结果 22例患者中CR 0例,PR 12例(54.5%),SD 9例(40.9%),PD 1例(4.5%),总有效率为54.5%。不良反应主要是血液学毒性、胃肠道反应,且均为Ⅰ~Ⅱ度。结论替吉奥胶囊单药治疗晚期胃癌近期疗效较好,不良反应可以耐受,对晚期胃癌患者,特别是年龄较大、一般状态较差的患者是安全有效的。 Objective To evaluate the efficacy and adverse effect of S-1 capsule on advanced gastric cancer.Methods A total of 22 patients with advanced gastric cancer were selected from January 2009 to January 2011.All enrolled patients received S-1,60mg,bid.The treatment lasted for 2 weeks followed by 1 week interval.The protocol was repeated every 3 weeks.All of the patients underwent the treatment for two cycles.Efficacy and toxicities were evaluated according to the RECIST1.1 standard.Results Of the 22 patients,CR was in 0,PR was in 12(54.5%),SD was in 9(40.9%) and PD was in 1(4.5%),The total response rate was 54.5%.The major toxic reactions were hematological and digestive toxic reactions.Conclusion S-1 single-drug regimen achieved relatively satisfactory short-term efficacy in the treatment of advanced gastric cancer especially for old patients.
出处 《实用癌症杂志》 2013年第1期56-57,共2页 The Practical Journal of Cancer
关键词 替吉奥胶囊 晚期胃癌 S1 Capsule Advanced Gastric Cancer
  • 相关文献

参考文献8

  • 1Rosati G,Ferrara D,Manzione L. New perspectives in the treatment of advanced or metastatic gastric cancer[J].World Journal of Gastroenterology,2009,(22):2689.doi:10.3748/wjg.15.2689.
  • 2孙燕;石元凯.临床肿瘤内科手册[M]北京:人民卫生出版社,2007476.
  • 3汤钊猷.现代肿瘤学[M]上海:上海医科大学出版社,2000730.
  • 4Makt-Manino M,Malnino K. Clinical studies of three oral prodrug of 5-fluorouracil(capecitabine,UFTS-1):a review[J].Oncologist(The),2002,(04):288.
  • 5Lee JL,Kang YK,Kang HJ. A randomized multi-centre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer[J].British Journal of Cancer,2008,(04):584.
  • 6Tanaka F,Fukuse T,wada H. The history mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents[J].Current Pharmaceutical Biotechnology,2000,(02):137.
  • 7Aral W,Hosoya Y,Hyodo M. Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1[J].Int J Chin Oncol,2007,(02):146.
  • 8Kawamurs S,Kataoka Y,Kimura H. A case of TS-1 resistant recurrent gastric cancer with lung metastasis responding to TS-1 and irinotecan combination therapy[J].Gan To Kagaku Ryoho(Japanese Journal of Cancer and Chemotherapy),2007,(04):615.

同被引文献126

引证文献14

二级引证文献118

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部